Patient Square Capital’s Perspective Therapeutics CATX Stock Holding History

Patient Square Capital’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,625,000	Closed	-$6.78M	–	25
2026 Q1	$6.78M	Buy	1,625,000 +492,185	+43%	+$2.08M	1.2%	22
2025 Q4	$3.12M	Buy	1,132,815 +783,492	+224%	+$2.24M	0.67%	27
2025 Q3	$1.2M	Buy	+349,323	New	+$1.27M	0.32%	23

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Patient Square Capital's CATX Position: Q2 2026 in Review

Patient Square Capital sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 1,625,000 shares — an estimated $6.78M sold.

Patient Square Capital first reported a position in CATX in Q3 2025 and held it in 3 quarters. The position peaked at $6.78M in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

Patient Square Capital reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
Patient Square Capital sold 1,625,000 Perspective Therapeutics shares in Q2 2026, an estimated $6.78M.
Patient Square Capital first reported a position in Perspective Therapeutics in Q3 2025 and held it in 3 quarters.
Patient Square Capital's Perspective Therapeutics position peaked at $6.78M in Q1 2026.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.